Current location:Cultural Crossings news portal > sport
WHO endorses China's Sinopharm COVID
Cultural Crossings news portal2024-05-22 02:41:14【sport】4People have gathered around
IntroductionWorkers prepare to unload the COVID-19 vaccines from China at the Baghdad International Airport in B
Workers prepare to unload the COVID-19 vaccines from China at the Baghdad International Airport in Baghdad, Iraq, April 11, 2021. [Photo/Xinhua]
The World Health Organization (WHO) validated on Friday the COVID-19 vaccine developed by China's Sinopharm for emergency use, a move set to boost global vaccine rollout, particularly in the developing world.
"This afternoon, the WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," said WHO Director General Dr. Tedros Adhanom Ghebreyesus at a press briefing.
"This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine," he said.
COVAX is a global coalition that works to ensure fair and equitable access to COVID-19 vaccines around the world.
In addition to the Sinopharm's BBIBP-CorV vaccine, the WHO had previously listed the COVID-19 vaccine developed by Pfizer/BioNTech, two versions of the AstraZeneca/Oxford vaccine, the Janssen vaccine and the Moderna vaccine for emergency use.
In an official press release, WHO Assistant Director General for Access to Health Products Dr. Mariangela Simao said that the addition of the Sinopharm vaccine has "the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk."
First COVID-19 jab with vial monitor
The jab produced by the Beijing Bio-Institute of Biological Products Co. Ltd., a subsidiary of the China National Biotec Group, is an inactivated vaccine with easy storage requirements, which makes it highly suitable for use in low-resource settings.
It is also the first vaccine that will carry a vial monitor, a small sticker on the vials that changes color if the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.
According to the WHO's Strategic Advisory Group of Experts on Immunization (SAGE), the Sinopharm vaccine is recommended for use in adults 18 years and older in a two-dose schedule with a spacing of three to four weeks.
Though few adults over 60 years were enrolled in clinical trials and efficacy could not be estimated in this age group, the WHO is not recommending an upper age limit for the Sinopharm vaccine, because reviewed data have suggested that the vaccine is likely to have a protective effect in older persons, according to the WHO press release.
"There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations," said the WHO press release, which recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring.
Assessment by SAGE has shown that the Sinopharm vaccine had been authorized by 45 countries or jurisdictions for use in adults 18 years or older, where more than 65 million doses had been administered through emergency use programs. No safety concerns have been identified from pre-clinical or repro/tox (reproductive toxicity) studies, while most adverse events were mild to moderate, such as injection pain, headache and fatigue.
Global public good
As of Wednesday, more than 1.1 billion COVID-19 vaccine doses had been administered globally, but over 80 percent of those had been administered in high and upper-middle income countries, while just 0.3 percent in low-income countries, according to Tedros.
With the WHO's validation for emergency use, the Sinopharm vaccine, as the first COVID-19 vaccine developed by a non-western country, is expected to accelerate vaccine rollout in many low and middle-income countries through purchase and delivery by the WHO-led COVAX initiative.
According to Yu Qingming, chairman of the Sinopharm Group, this year's output of the Sinopharm vaccine is targeted at more than one billion doses, and is expected to reach three billion doses in the future.
China has decided to provide ten million COVID-19 vaccine doses to the COVAX initiative to meet the urgent needs of developing countries, a concrete step to deliver on the promise to make vaccines a global public good.
This is also an important achievement in the field of epidemic prevention and control. China was the first to have put the pandemic under control, and successfully developed one of the earliest vaccines in the world.
Adhering to the concept of a community with a shared future for health, China has so far provided vaccine assistance selflessly to more than 80 countries and three international organizations, exported vaccines to more than 40 countries, and collaborated with over ten countries in vaccine research and development (R&D) and production.
The validation of the Chinese vaccine, which is the result of high technology content and high R&D investment, has also strengthened the international recognition of the "Made in China" and "R&D in China labels."
Address of this article:http://samoa.unhasdecoradas.org/news-13f999923.html
Very good!(11)
Related articles
- Ricky Stenhouse punching Kyle Busch could lead to suspension
- Scenery of cole flowers in Mugang Township, China's Guizhou
- Macron, Le Pen lead 1st round of French presidential election
- Xi Calls for More Innovations in Party's Theories
- Grant Shapps vows he WILL find more planes for mass parachute drop to mark 80th anniversary of D
- Follow Xi's Steps: Why Did President Xi Visit Suzhou Industrial Park?
- NetEase Inc renews game partnership with Blizzard
- Spring scenery across China
- Israeli army says it kills over 130 militants in E. Rafah
- People enjoy Labor Day holiday across China
Popular articles
Recommended
Sale continues dominant run as Braves beat Padres 3
Xi Inspects Suzhou in East China's Jiangsu Province
NetEase Inc renews game partnership with Blizzard
Xi Focus: Xi Calls for More Achievements in Party's Theoretical Innovation
Shohei Ohtani's first walk
Ukraine extends martial law
Xi Meets Russian Federation Council Speaker
Polar icebreaker Xuelong 2 receives warm welcome in Hong Kong
Links
- 'Wearing garden on the head' in Fujian attracts visitors
- Xinjiang's 17
- Israel stands strong: IDF reveals it has shot down more than 200 drones and missiles fired by Iran
- How brave Louise Thompson's life has changed from her reality TV days: From a fun
- Event celebrating upcoming Chinese New Year held in China's Hong Kong
- New building of museum at Shang Dynasty capital site to open this month
- McCutchen's 300th homer, Suwinski's grand slam leads Pirates over Phillies 9
- China's NCPA to host Festival Waltz concert
- Holliday's first hit helps the Orioles rally to a 6
- China launches campaign to combat movie piracy during Spring Festival holiday